Julie Marie Kelly, MSN, APRN, NP-C
Family · Mountain View
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Julie Marie Kelly’s office at (918) 607-4135 to ask if they take your plan before you enroll.
Original Medicare doctor bills
$5,529
Medicare paid this office $5,529 for 59 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 41 | $3,258 | $69 |
| New patient visit (45+ min) | 14 | $999 | $71 |
| Injection of drug or substance under skin or into muscle | 11 | $104 | $9 |
Who their Medicare patients are
59 Original Medicare patients in 2024. Average age 72 · Women 58% · Health risk score 1.00. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Coronary heart disease 34% · Diabetes 24% · COPD 22% · Atrial fibrillation 19%.
The office billed $15,414, Medicare allowed $8,173 and paid $5,529; for 152 services of 22 kinds; $12 of it was for drugs given in the office and $5,517 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 59 | 152 | 72 | 1.00 | $15,414 | $5,529 |
| 2023 | 59 | 438 | 63 | 1.51 | $53,058 | $27,506 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Return visit (30+ min) | 33 | $5,342 | $75 |
| Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 11 | $5,259 | $195 |
| Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 20 | $4,477 | $149 |
| Testing for presence of drug, by chemistry analyzers | 24 | $3,008 | $59 |
| Short return visit (20+ min) | 29 | $2,356 | $56 |
Medicaid work
$22,396 in 2024
Medicaid paid $22,396 for 209 billed services this clinician did in 2024, up to 41 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 165 | $18,245 |
| Short return visit (20+ min) | 31 | $2,344 |
| New patient visit (45+ min) | 13 | $1,807 |
| 2024 | 209 | 3 | 41 | $22,396 |
| 2023 | 1,319 | 5 | 144 | $111,248 |
| 2022 | 794 | 11 | 44 | $52,478 |
| 2021 | 511 | 6 | 30 | $36,169 |
| 2020 | 128 | 4 | 25 | $5,577 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 655 | $67,810 |
| Short return visit (20+ min) | 528 | $39,044 |
| Short return visit | 87 | $4,038 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 28 | $209 |
| Brief emotional/behavioral assessment (eg, depression inventory, attention-deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument | 21 | $147 |
2022
| Short return visit (20+ min) | 245 | $18,575 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 103 | $9,700 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 93 | $8,184 |
| Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered | 176 | $8,088 |
| Short return visit | 66 | $3,124 |
| Return visit (30+ min) | 22 | $2,535 |
| Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; infant (age younger than 1 year) | 12 | $1,177 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 21 | $986 |
| Developmental screening | 13 | $108 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 29 | $0 |
| Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use | 14 | $0 |
2021
| Short return visit (20+ min) | 191 | $14,324 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 112 | $9,964 |
| Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered | 149 | $6,933 |
| Return visit (30+ min) | 25 | $2,881 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 13 | $1,227 |
| Short return visit | 21 | $841 |
2020
| Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered | 77 | $3,239 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 26 | $2,338 |
| Haemophilus influenzae type b vaccine, PRP-OMP conjugate | 12 | $0 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 13 | $0 |
Drugs they prescribed that Part D paid
$82,480
Pharmacies billed $82,480 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
347 generic and fewer than 11 brand-name prescriptions · $82,480 in drug cost · 66 antibiotic prescriptions to 60 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Albuterol Sulfate Hfa | 13 | $243 | $19 |
| Ondansetron Odt | 18 | $179 | $10 |
| Cyclobenzaprine | 14 | $134 | $10 |
| Amoxicillin-Clavulanate Potass | 13 | $107 | $8 |
| Pantoprazole | 11 | $67 | $6 |
See all 7 drugs
| Albuterol Sulfate Hfa | 13 | $243 | $19 |
| Ondansetron Odt | 18 | $179 | $10 |
| Cyclobenzaprine | 14 | $134 | $10 |
| Amoxicillin-Clavulanate Potass | 13 | $107 | $8 |
| Pantoprazole | 11 | $67 | $6 |
| Azithromycin | 15 | $54 | $4 |
| Meloxicam | 11 | $26 | $2 |
Year by year
| 2024 | 413 | 152 | None | None | $82,480 |
| 2023 | 987 | 143 | 4% (35) | None | $290,541 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 29 drugs
| Humira | 11 | $107,076 | $9,734 |
| Mounjaro | 27 | $29,980 | $1,110 |
| Ozempic | 15 | $20,084 | $1,339 |
| Trulicity | 15 | $15,344 | $1,023 |
| Buprenorphine-Naloxone | 44 | $13,125 | $298 |
| Trelegy Ellipta | 14 | $9,739 | $696 |
| Xarelto | 11 | $6,759 | $614 |
| Naloxone | 16 | $1,438 | $90 |
| Cyclobenzaprine | 71 | $910 | $13 |
| Gabapentin | 48 | $722 | $15 |
| Pregabalin | 24 | $682 | $28 |
| Hydroxyzine | 16 | $632 | $39 |
| Buprenorphine | 11 | $487 | $44 |
| Albuterol Sulfate Hfa | 19 | $335 | $18 |
| Amitriptyline | 13 | $276 | $21 |
| Atorvastatin | 25 | $273 | $11 |
| Tramadol | 30 | $270 | $9 |
| Ondansetron Odt | 20 | $254 | $13 |
| Ketoconazole | 12 | $225 | $19 |
| Pantoprazole | 11 | $224 | $20 |
| Tizanidine | 21 | $213 | $10 |
| Omeprazole | 16 | $206 | $13 |
| Meloxicam | 39 | $185 | $5 |
| Levothyroxine | 17 | $124 | $7 |
| Ondansetron | 16 | $123 | $8 |
| Lisinopril | 15 | $100 | $7 |
| Triamcinolone Acetonide | 13 | $66 | $5 |
| Amlodipine Besylate | 11 | $51 | $5 |
| Hydrochlorothiazide | 11 | $44 | $4 |
Money from drug and device companies
$18 in 2024
| 2024 | 1 | 1 | None | $18 |
| 2023 | 9 | 15 | None | $276 |
| 2022 | 6 | 6 | None | $213 |
| 2021 | 3 | 4 | None | $86 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Dalvance | $18 | 1 payment
|
See the published payment
| Abbvie | Meals · 2024-06-13 | Dalvance | $18 |
See earlier years (2023, 2022, 2021)
2023: $276
| Orexo US | Zubsolv | $53 | 3 payments
|
| Pfizer | Prevnar 20 | $40 | 2 payments
|
| Supernus Pharmaceuticals | Qelbree | $39 | 2 payments
|
| Currax Pharmaceuticals | Nexletol | $39 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Relistor | $32 | 2 payments
|
| Indivior | Sublocade | $20 | 1 payment
|
| Lilly USA | Trulicity | $19 | 1 payment
|
| Sanofi Pasteur | Beyfortus | $18 | 1 payment
|
| GlaxoSmithKline | Bexsero | $15 | 1 payment
|
2022: $213
| GlaxoSmithKline | Bexsero | $122 | 1 payment
|
| Sobi | Synagis | $21 | 1 payment
|
| Sanofi Pasteur | Menquadfi | $21 | 1 payment
|
| Supernus Pharmaceuticals | Qelbree | $17 | 1 payment
|
| Pfizer | Eucrisa | $16 | 1 payment
|
| Corium | Azstarys | $16 | 1 payment
|
2021: $86
| Takeda Pharmaceuticals U.S.A. | Vyvanse | $48 | 2 payments
|
| Sanofi Pasteur | Vaxelis | $20 | 1 payment
|
| Pfizer | Eucrisa | $18 | 1 payment
|
Professional record
- NPI
- 1104435999
- Licence
- FL APRN11019613
More record details
- Sole proprietor
- No
- Medicaid ID
- FL 114460100
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 2525 Charleston Rd Ste 104, Mountain View, CA, 94043
- NPI first listed
- 2020-07-28
- NPI last updated
- 2025-07-31
- NPI record certified
- 2025-07-31
This is when the NPI record was last certified, not a medical board exam.